120 related articles for article (PubMed ID: 34168381)
21. Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.
Rhiem K; Schmutzler R
Breast Care (Basel); 2014 Dec; 9(6):385-9. PubMed ID: 25759620
[TBL] [Abstract][Full Text] [Related]
22. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
23. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
24. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Górski B
Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
[TBL] [Abstract][Full Text] [Related]
25. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
26. Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer.
Grimmett C; Pickett K; Shepherd J; Welch K; Recio-Saucedo A; Streit E; Seers H; Armstrong A; Cutress RI; Evans DG; Copson E; Meiser B; Eccles D; Foster C
Patient Educ Couns; 2018 May; 101(5):779-788. PubMed ID: 29225062
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations.
Unic I; Verhoef LC; Stalmeier PF; van Daal WA
Med Decis Making; 2000; 20(3):251-62. PubMed ID: 10929847
[TBL] [Abstract][Full Text] [Related]
28. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
29. Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
Huber D; Seitz S; Kast K; Emons G; Ortmann O
Arch Gynecol Obstet; 2020 Sep; 302(3):715-720. PubMed ID: 32719921
[TBL] [Abstract][Full Text] [Related]
30. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
31. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
32. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
33. Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Cullinane CM; Creavin B; O'Connell EP; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
Br J Surg; 2020 Jul; 107(8):951-959. PubMed ID: 32297664
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
35. Decision aids for people facing health treatment or screening decisions.
O'Connor AM; Bennett CL; Stacey D; Barry M; Col NF; Eden KB; Entwistle VA; Fiset V; Holmes-Rovner M; Khangura S; Llewellyn-Thomas H; Rovner D
Cochrane Database Syst Rev; 2009 Jul; (3):CD001431. PubMed ID: 19588325
[TBL] [Abstract][Full Text] [Related]
36. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
37. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
38. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I
Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513
[TBL] [Abstract][Full Text] [Related]
39. Interactive patient decision aids for women facing genetic testing for familial breast cancer: a systematic web and literature review.
Williams L; Jones W; Elwyn G; Edwards A
J Eval Clin Pract; 2008 Feb; 14(1):70-4. PubMed ID: 18211647
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
